Abcam, ab236121, Anti-HNRNPA0 antibody [EP16085] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal HNRNPA0 antibody. Carrier free. Suitable for WB, ICC/IF, Flow Cyt (Intra), IHC-P and reacts with Human, Mouse, Rat samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EP16085,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Mouse, Rat, Human,
Applications:IHC-P, Flow Cyt (Intra), ICC/IF, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab236121 is the carrier-free version of
ab197023
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The heterogeneous nuclear ribonucleoprotein A0 (HNRNPA0) is a protein involved in RNA binding and regulation of RNA metabolism. Commonly referred to as HNRNPA0 it has a molecular mass close to 34 kDa. This protein is expressed in a variety of tissues including brain liver and spleen suggesting its widespread functional relevance. HNRNPA0 plays a role in the post-transcriptional regulation of gene expression by influencing mRNA stability and splicing.
Biological function summary
HNRNPA0 modulates RNA processing and is actively involved in mRNA decay and stabilization processes. It forms complexes with other hnRNP proteins and interacts with mRNA substrates to regulate their fate within the cell. This protein contributes to gene expression regulation under stress conditions by altering the stability of specific mRNAs. Such regulation is important for maintaining proper cellular responses to external stress factors.
Pathways
HNRNPA0 is involved in the p38 MAPK signaling pathway where it influences the stability of mRNAs encoding inflammatory mediators. It also plays a part in the apoptotic pathway where it interacts with proteins such as TRAF2 and apoptosis as death domain-like protein (ADRP). Through these pathways HNRNPA0 contributes to cellular stress responses inflammation and programmed cell death linking it to essential cellular processes.
HNRNPA0 has been implicated in neurodegenerative diseases like amyotrophic lateral sclerosis (ALS) where protein aggregates may form due to dysregulation of HNRNPA0 activity. It is also associated with certain types of cancer such as leukemia where altered expression levels may impact mRNA stability and cell proliferation. Through these disease contexts HNRNPA0 interacts with proteins like TDP-43 in ALS and has connections to proto-oncogenes in cancer highlighting its potential role as a therapeutic target.